Latest 8-K filings

Odysight.ai announced strong backlog growth to $16.45 million and secured new purchase orders from Boeing and Elbit Systems, alongside a Honeywell Aerospace PoC, despite a year-over-year revenue decrease in H1 2026.

Cytokinetics has filed a complaint against Bristol-Myers Squibb and MyoKardia, seeking a declaratory judgment of non-infringement and invalidity of a specific patent.

Ideal Power reports Q2 2026 progress with B-TRAN technology, advancing solid-state circuit breaker projects and securing a high-volume foundry agreement, despite continued net losses.

Bit Digital announced its second quarter 2026 financial results, showcasing revenue growth across infrastructure businesses and improved operating cash flow, funded by a treasury-backed financing.

Innovative Aerosystems reported a strong third quarter with 10.7% revenue growth to $26.7 million, driven by increased gross margins and significant improvements in net income and adjusted EBITDA.

Universal Health Services, Inc. has entered into an underwriting agreement to issue and sell $1.1 billion in senior secured notes across two tranches.

ConnectM Technology Solutions reports an increase in the illustrative value of its stake in Blue Cloud Softech Solutions following Blue Cloud's $150 million technology services agreement with SpaceX International Ltd.

Banner Corporation's proposed merger with Pacific Financial Corporation has received approval from the Washington State Department of Financial Institutions, moving closer to completion.

WaterBridge Infrastructure LLC announces a $100 million offering of additional senior notes due 2033 to fund its revolving credit facility, signaling expansion and debt management.

Faraday Future Intelligent Electric Inc. announced that its stockholders approved a private placement proposal to issue senior convertible promissory notes, crucial for its Embodied AI Robotics development and 2026 deliveries.

ADC Therapeutics reported Q2 2026 financial results with $18.6M in net product revenue, but faces FDA concerns over LOTIS-5 trial data and announced a 17% workforce reduction.

Live Ventures Incorporated announced its fiscal third quarter 2026 financial results, reporting a decrease in revenue and a net loss, contrasting with a profitable prior-year period.

BK Technologies announced double-digit revenue growth, expanded gross margins to 51.9%, and a record cash balance of $29.9 million for Q2 FY26.

Comstock Holding Companies, Inc. announced robust second quarter 2026 financial results, featuring a 74% surge in revenue to $22.6 million and a 512% increase in net income.

Saga Communications, Inc. announced a 6.5% decrease in net revenue for Q2 2026 to $26.4 million and a net loss of $1.4 million for the six-month period.

SINTX Technologies announced it has regained compliance with Nasdaq's minimum stockholders equity requirement, closing a previously disclosed deficiency matter.

OptimumBank Holdings announced record second-quarter 2026 earnings, surpassing $1.4 billion in total assets, driven by a relationship-based banking strategy and disciplined credit culture.

Biofrontera Inc. announced robust second quarter 2026 financial results, highlighted by a 32.9% increase in net product revenue to $12.0 million and a significant improvement in gross margin to 80%.

RenX Enterprises Corp. announced record second-quarter 2026 revenue of $4.26 million, driven by sequential growth in its two primary operating segments, alongside continued profitability in its Logistics segment.

Lifeway Foods announced record-breaking quarterly net sales of $66.9 million, marking the 27th consecutive quarter of year-over-year growth, despite facing temporary margin headwinds from elevated milk and packaging costs.

Aeternum Health has acquired an option to purchase a 51% stake in the Nkamouna Nickel-Cobalt-Manganese mining project in Cameroon, signaling a strategic move into critical mineral production.

Dogwood Therapeutics announced its second quarter 2026 financial results, highlighting progress in its Halneuron Phase 2b trial and a new development partnership, while also reporting a substantial non-cash impairment charge.

Bed Bath & Beyond, Inc. announces the appointment of Jill Windrum as Chief Accounting Officer and Deputy Chief Financial Officer, effective August 31, 2026.

Cingulate Inc. announced its second quarter 2026 financial results, highlighting $28.4 million in cash, progress on CTx-1301 manufacturing, and a new patent, while navigating a delayed NDA resubmission.

PDS Biotechnology Corporation announced a strategic refocus on its PDS0301 program, discontinuing the VERSATILE-003 Phase 3 trial for PDS0101 and reporting a net loss of $9.8 million for Q2 2026.

Ovid Therapeutics reported Q2 2026 business updates and financial results, highlighting progress in its OV4071 and OV329 programs, a strategic soticlestat transaction, and strengthened leadership.

Fate Therapeutics announced second quarter 2026 financial results, highlighting progress in its CAR T-cell therapy pipeline, including patient dosing in a Phase 2 trial for lupus nephritis and FDA clearance for a new autoimmune trial.

HeartCore Enterprises announced second quarter 2026 financial results, showing a 71.6% revenue increase to $321,000 but a net loss of $2.0 million, a significant shift from the prior year's net income.

Tron Inc. announced a strategic initiative to deepen its integration with the TRON DAO ecosystem and pursue Super Representative status, aiming to generate recurring on-chain revenue.

FitLife Brands reported a 65% revenue increase in Q2 2026, largely due to the Irwin Naturals acquisition, alongside sequential growth and improved EPS.